Samsung bioepis and teva enter into a strategic partnership for commercialization of epysqli® (eculizumab-aagh) in the united states

Incheon, korea and tel aviv, israel, jan. 10, 2025 (globe newswire) -- samsung bioepis co., ltd. and teva pharmaceutical industries ltd. (nyse: and tase: teva) announced today that the companies have entered into a license, development and commercialization agreement for epysqli® (eculizumab-aagh), samsung bioepis' biosimilar to soliris® i (eculizumab-aagh) in the united states (u.s.).
TEVA Ratings Summary
TEVA Quant Ranking